Apollomics(NASDAQ) APLMW

Market CapN/A

Since IPO (2021)-97%

5 YearN/A

1 Year+67%

1 Month-26%

$0.01

-0.71%

-0.00Today

Apollomics last closing stock price
Metric	Price	Date
Last close	USD 0.01	2026-08-28

Apollomics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+26.13%	USD 0.01	2026-08-21
1 month	-26.32%	USD 0.02	2026-07-29
3 month	+4.48%	USD 0.01	2026-05-29
Year to date	+26.13%	USD 0.01	2025-12-31
1 year	+66.67%	USD 0.01	2025-08-28
3 year	-77.81%	USD 0.06	2023-08-29
Since inception	-97.02%	USD 0.47	2021-11-26

Apollomics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$8.70M

Net Income (TTM)

-$64.80M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$0.01

Volume

4,569

Open

$0.01

Price

$0.01

Volume

4,569

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.23

Estimated Earnings Date

Sep 24, 2026

Dividend

$0.00

Beta (Volatility)

0.04 (Low)

Price

$0.01

Volume

4,569

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.23

Estimated Earnings Date

Sep 24, 2026

APLMW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Apollomics

Apollomics, Inc. is a clinical-phase biotechnology company focused on developing innovative cancer treatments to address significant unmet patient needs. Founded in 2015 and based in Foster City, California, the company aims to advance its pipeline of therapies through rigorous research and development.

Products and Services

Novel cancer therapies targeting various malignancies
Clinical trials to evaluate the efficacy and safety of treatments
Collaborations with research institutions for drug development

Growth Outlook

Recent quarterly revenue reached $8.5 million, indicating potential market traction
Strong focus on R&D with $9.11 million spent in the latest quarter
Plans to expand clinical trials, enhancing product pipeline and market presence

Financial Highlights

Market capitalization stands at approximately $233.5 million
Trailing twelve months (TTM) revenue of $8.5 million shows growth potential
Cash and cash equivalents of $3.28 million provide operational runway

Apollomics, Inc. operates in a competitive biotechnology landscape, focusing on unmet medical needs in cancer treatment. The company's recent revenue growth and substantial investment in research and development highlight its commitment to innovation. With a solid cash position, Apollomics is well-positioned to advance its clinical trials and expand its product offerings. The ongoing development of novel therapies could lead to significant advancements in cancer care, making Apollomics an intriguing prospect for investors interested in the biotechnology sector.

AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Foster City, CA 94404, US

APLMW Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-111.45%

Net Income Margin

-128.69%

Return on Equity

288.40%

Return on Capital

N/A

Return on Assets

-162.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

4.57K

Avg. Volume

97.73K

Financials (TTM)

Gross Profit

$8.70M

Operating Income

-$51.61M

EBITDA

-$50.53M

Operating Cash Flow

-$57.92M

Capital Expenditure

-$24.00K

Free Cash Flow

-$57.95M

Cash & ST Invst.

$3.28M

Total Debt

$643.00K

Apollomics Performance Analysis

Apollomics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	430.9%
Q4	2024-12-31	-188.8%
Q2	2025-06-30	641.4%
Q4	2025-12-31	-100.0%

Apollomics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-06-30	-15733.3%
Q4	2024-12-31	55.5%
Q2	2025-06-30	32.8%
Q4	2025-12-31	133.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$1.60M

+107.3%

EBITDA

$3.03M

+110.9%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Total Cash

$3.28M

-91.3%

Total Debt

$643.00K

-86.2%

Accounts Receivable

$2.49M

+434.3%

Inventory

$0.00

N/A

Long Term Debt

$434.00K

+62.5%

Short Term Debt

$209.00K

-95.2%

Return on Assets

-1.63%

N/A

Return on Invested Capital

-24.41%

N/A

Free Cash Flow

-$10.37M

+57.5%

Operating Cash Flow

-$10.37M

+57.5%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

KCPCKey Capital Corporation

KCPCKey Capital Corporation$0.00+0.00%

PGIEPGI Energy, Inc.

PGIEPGI Energy, Inc.$0.00+0.00%

PLMKPlum Acquisition Corp. IV

PLMKPlum Acquisition Corp. IV$10.65-0.75%

FGMCFG Merger II Corp.

FGMCFG Merger II Corp.$8.30+0.00%

TDACTranslational Development Acquisition Corp.

TDACTranslational Development Acquisition Corp.$10.85+0.09%

MLACMountain Lake Acquisition Corp. Class A

MLACMountain Lake Acquisition Corp. Class A$0.98-16.24%

HLOIPrevisto International Holdings Incorporated

HLOIPrevisto International Holdings Incorporated$0.00+30.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About APLMW

What is the current price of Apollomics?

Apollomics is trading at $0.01 per share.

What is the 52-week range for Apollomics?

Over the past 52 weeks, Apollomics has traded between $0.00 and $0.23.

How much debt does Apollomics have?

Apollomics total debt is unavailable.

How much cash does Apollomics have on hand?

Apollomics does not have cash on hand data available.

What is Apollomics’s dividend yield?

Apollomics does not currently have a dividend yield.

Apollomics(NASDAQ) APLMW

Apollomics Financials at a Glance

APLMW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Apollomics

APLMW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Apollomics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About APLMW

What is the current price of Apollomics?

What is the 52-week range for Apollomics?

How much debt does Apollomics have?

How much cash does Apollomics have on hand?

What is Apollomics’s dividend yield?

Premium Investing Services